Fixed-dose amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide significantly reduced systolic blood pressure from baseline (95% CI for mean absolute difference -38.76 to -35.46; p<0.001).
Observational (n=880)
Yes
Do fixed-dose combinations of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide reduce blood pressure in patients with arterial hypertension?
Fixed-dose combinations of amlodipine/valsartan with or without hydrochlorothiazide effectively and safely reduce blood pressure in routine clinical practice.
p-value: p=<0.001
Objective: To assess the clinical effectiveness of fixed-dose combinations of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in the management of arterial hypertension in Armenia.Design and method: Medical records of patients receiving fixed-dose amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide were analyzed within the framework of the multicenter, non-interventional CHOICE study. Hypertension was diagnosed in routine clinical practice. Treatment was administered in various dosing regimens according to physician discretion. Data on medical history, physical examination findings, and blood pressure measurements were extracted from patient records. Safety outcomes were also assessed. The follow-up period lasted 12 weeks. Results: A total of 880 patients were included into the analysis, 47% (n=414) of women and 53% (n=466) of men. The average age was 61.4 years. A significant reduction in the levels of systolic (SBP), diastolic BP (DBP) was found at the end of the study in all study groups (p<0.001). This demonstrated an adequate antihypertensive effect of all treatment regimens. 95%-CI for mean absolute difference SBP in treatment groups ranged -38.76, -35.46 (p<0.001); 95%-CI for mean absolute difference DBP -17.68,-15.47. In the Capture 3 reaching blood pressure target below 140/90 mmHg level was 73.1% with office BP measurement data, and 80,7% with respect to patient measured BP. 97,9% of patients finished the study without any adverse reaction. The most common adverse reaction was peripheral edema (1,9%). Conclusions: Therapy resulted in a significant reduction in blood pressure in all treatment groups compared with baseline levels. A dose-dependent reduction in SBP levels was found in all treatment groups. The tolerability of all treatment regimens was good.
Hayrapetyan et al. (Fri,) conducted a observational in arterial hypertension (n=880). Fixed-dose amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide vs. baseline was evaluated on mean absolute difference in systolic blood pressure (SBP) (95% CI -38.76 to -35.46, p=<0.001). Fixed-dose amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide significantly reduced systolic blood pressure from baseline (95% CI for mean absolute difference -38.76 to -35.46; p<0.001).